Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-3.17% $7.03
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 348.02 mill |
EPS: | -1.930 |
P/E: | -3.64 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 49.50 mill |
Avg Daily Volume: | 0.183 mill |
RATING 2024-04-17 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.64 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.62x |
Company: PE -3.64 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.543 (-92.27%) $-6.49 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 6.53 - 7.53 ( +/- 7.08%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Kilroy Conor | Buy | 144 000 | Stock Option (Right to Buy) |
2024-04-02 | Kilroy Conor | Buy | 96 000 | Common Stock |
2024-04-01 | Kilroy Conor | Buy | 0 | |
2024-03-15 | Plavsic Mark | Sell | 0 | Common Stock |
2024-03-15 | Plavsic Mark | Sell | 138 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
86.98 |
Last 96 transactions |
Buy: 15 662 380 | Sell: 3 253 163 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.03 (-3.17% ) |
Volume | 0.138 mill |
Avg. Vol. | 0.183 mill |
% of Avg. Vol | 75.67 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $8.04 | N/A | Active |
---|
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.